These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 866697)

  • 1. Neurological and electroencephalographic changes in newborns treated with prostaglandins E1 and E2.
    Fariello R; Olley PM; Coceani F
    Prostaglandins; 1977 May; 13(5):901-7. PubMed ID: 866697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administration of prostaglandin E1 in neonates with critical congenital cardiac defects.
    Lewis AB; Takahashi M; Lurie PR
    J Pediatr; 1978 Sep; 93(3):481-5. PubMed ID: 690772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of alprostadil (prostaglandin E1) in the management of congenital heart disease in infancy.
    Heymann MA; Clyman RI
    Pharmacotherapy; 1982; 2(3):148-55. PubMed ID: 6763200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prostaglandins E1 in the treatment of neonatal cardiopathies related to ductus arteriosus. 19 cases].
    Maesen Y; Bosi G; Stijns M; Vliers A
    Arch Mal Coeur Vaiss; 1981 May; 74(5):579-85. PubMed ID: 6794479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term prostaglandin E1 therapy in congenital heart defects.
    Teixeira OH; Carpenter B; MacMurray SB; Vlad P
    J Am Coll Cardiol; 1984 Mar; 3(3):838-43. PubMed ID: 6537955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostaglandin E1 in suspected ductus dependent cardiac malformation.
    Hallidie-Smith KA
    Arch Dis Child; 1984 Nov; 59(11):1020-6. PubMed ID: 6542338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic use of prostaglandin E1 in infant with congenital heart disease.
    Heymann MA
    Am Heart J; 1981 Jun; 101(6):837-43. PubMed ID: 7234660
    [No Abstract]   [Full Text] [Related]  

  • 8. Oral administration of prostaglandin E2 in the hypoplastic left heart syndrome.
    Fujiseki Y; Yamamoto H; Hattori M; Yamawaki Y; Goto M; Shimada M
    Jpn Heart J; 1983 May; 24(3):481-7. PubMed ID: 6576179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostaglandin treatment of newborns with ductal-dependent congenital heart disease.
    Linday LA; Engle MA
    Pediatr Ann; 1981 Apr; 10(4):29-38. PubMed ID: 7232040
    [No Abstract]   [Full Text] [Related]  

  • 10. Alprostadil (Prostin VR Pediatric Sterile Solution, The Upjohn Company).
    Roehl SL; Townsend RJ
    Drug Intell Clin Pharm; 1982 Nov; 16(11):823-32. PubMed ID: 6756848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of prostaglandin E1 and E2 in the management of neonatal heart disease.
    Olley PM; Coceani F; Rowe RD
    Adv Prostaglandin Thromboxane Res; 1978; 4():345-53. PubMed ID: 645511
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacological manipulation of the ductus arteriosus.
    Silove ED
    Arch Dis Child; 1986 Sep; 61(9):827-9. PubMed ID: 3767410
    [No Abstract]   [Full Text] [Related]  

  • 13. Prostaglandin E1 in infants with pulmonary atresia.
    Weir EK; Matisonn RE; Losman E; Chesler E
    S Afr Med J; 1978 Oct; 54(17):700-2. PubMed ID: 741285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Skeletal side effects of treatment with prostaglandin E1].
    Persigehl M; Hövels-Gürich H; von Bernuth G
    Rofo; 1984 Oct; 141(4):427-30. PubMed ID: 6436918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prostaglandin E1 therapy in infants with cyanotic congenital heart malformations: hemodynamic and angiographic findings (author's transl)].
    Schumacher G; Mocellin R; Schöber JG; Kellner M; Bühlmeyer K
    Klin Padiatr; 1978 Sep; 190(5):465-73. PubMed ID: 568198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morphologic features of the ductus arteriosus after prostaglandin E1 administration for ductus-dependent congenital heart defects.
    Park IS; Nihill MR; Titus JL
    J Am Coll Cardiol; 1983 Feb; 1(2 Pt 1):471-5. PubMed ID: 6681824
    [No Abstract]   [Full Text] [Related]  

  • 17. Prostaglandins and the management of congenital heart disease.
    Taylor WJ; Alpert BS
    Am Fam Physician; 1982 Dec; 26(6):127-32. PubMed ID: 6890758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of oral and low dose intravenous prostaglandin E2 in management of ductus dependent congenital heart disease.
    Silove ED; Roberts DG; de Giovanni JV
    Arch Dis Child; 1985 Nov; 60(11):1025-30. PubMed ID: 3865636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proceedings: Emergency treatment of certain cyanotic heart defects with prostaglandin E2.
    Olley PM; Coceani F
    Br Heart J; 1976 Aug; 38(8):877. PubMed ID: 973917
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of prostaglandins in cardiopulmonary diseases of the newborn.
    Olley PM; Coceani F
    Semin Perinatol; 1980 Apr; 4(2):135-41. PubMed ID: 6990504
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.